SYNCROSOME is proud to announce that it has joined the ETAP-Lab group – an offshoot of the preclinical CRO ETAP-Lab.
🚀 This acquisition marks a new stage in the company’s development.
Since its inception in 2000, SYNCROSOME has established itself as a key player in French preclinical research. In joining the ETAP-Lab group, SYNCROSOME is now bringing its expertise and innovative models to bear on in vivo evaluation of therapeutic strategy efficacy in cardiorespiratory medicine. SYNCROSOME’s expertise will also bolster ETAP-Lab’s historical activity in the field of neurology.
Given the synergies in terms of skills, technologies and scientific networks, this coming-together of the two laboratories will also strengthen the overall capabilities of the ETAP-Lab group. Moreover, SYNCROSOME will be able to draw on the scientific, technical, commercial and legal support of the ETAP-Lab group to accelerate development in its core areas of excellence, in line with the group’s overall strategy.
Nicolas Violle, who is now CEO of both SYNCROSOME and ETAP-Lab, has this to say: « I am especially pleased to be working with Sandra Robelet and her team of scientists, whose expertise has consistently impressed me in the course of the year we have spent preparing this acquisition. I am also very confident that SYNCROSOME will be successfully integrated into the vision and growth strategy of the ETAP-Lab Group.
To find out more, please read our official press release.
Keep an eye on our feed to hear all about this new adventure!